We are live on
!
Find out more
SRCM
Swift Run Capital Management Portfolio holdings
AUM
$51.8M
1-Year Est. Return
6.71%
This Fund
S&P 500
This Quarter
Est. Return
+5.93%
1 Year Est. Return
+6.71%
3 Year Est. Return
+9.9%
5 Year Est. Return
+45.98%
10 Year Est. Return
–
AUM
$76.3M
AUM Growth
-$31M
(-29%)
Cap. Flow
-$31.3M
Cap. Flow
% of AUM
-41.02%
Top 10 Holdings %
Top 10 Hldgs %
77.19%
Holding
39
New
1
Increased
–
Reduced
20
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$194K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Goldman Sachs
GS
|
+$6.75M |
| 2 |
Huntsman Corp
HUN
|
+$2.63M |
| 3 |
Marathon Petroleum
MPC
|
+$2.63M |
| 4 |
Comcast
CMCSA
|
+$2.01M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$1.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 21% |
| 2 | Energy | 16.52% |
| 3 | Materials | 11.13% |
| 4 | Communication Services | 9.21% |
| 5 | Real Estate | 6.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Johnson & Johnson
JNJ
$618B
| $292K | 0.38% |
2,000
| – | – |
|
27
Becton Dickinson
BDX
$45.6B
| $283K | 0.37% |
1,066
| – | – |
|
28
Procter & Gamble
PG
$336B
| $250K | 0.33% |
2,000
| – | – |
|
|
29
Pfizer
PFE
$143B
| $202K | 0.26% |
+5,433
| New | +$194K |
|
30
Nuveen Floating Rate Income Fund
JFR
$1.24B
| $102K | 0.13% |
10,000
| – | – |
|
31
Citigroup
C
$222B
| $51K | 0.07% |
64,187
-14,393
| -18% | -$1.06M |
|
32
CervoMed
CRVO
$23.9M
| $7K | 0.01% |
194
| – | – |
|
33
Alerian MLP ETF
AMLP
$13B
| – | – |
-14,864
| Closed | -$679K |
|
34
Air Products & Chemicals
APD
$65.7B
| – | – |
-1,054
| Closed | -$234K |
|
35
Enterprise Products Partners
EPD
$82.3B
| – | – |
-16,000
| Closed | -$457K |
|
|
36
Goldman Sachs
GS
$300B
| – | – |
-32,579
| Closed | -$6.75M |
|
37
JPMorgan Chase
JPM
$935B
| – | – |
-2,315
| Closed | -$272K |
|
38
Viasat
VSAT
$10.6B
| – | – |
-2,730
| Closed | -$206K |
|
Similar funds
HS
OFM
UMA
XM
NISOA
IWA
FC
HA
Swift Run Capital Management's Q4 2019 Portfolio in Review
As of Q4 2019, Swift Run Capital Management held 39 positions worth $76.3M, down 29% from $107M the previous quarter. Its ten largest holdings account for 77% of the portfolio.
Swift Run Capital Management withdrew a net $31.3M in Q4 2019, closing 6 positions and reducing 20 holdings. Its most notable exit was Goldman Sachs, an estimated $6.75M position sold in full.
By sector, the portfolio is most concentrated in Financials at 21% of assets, down from 29% a quarter earlier, followed by Energy and Materials.
Against the trend, Swift Run Capital Management opened a new position in Pfizer worth $202K.
- Swift Run Capital Management's largest Q4 2019 buy was Pfizer: 5,433 shares worth $202K.
- Swift Run Capital Management's biggest Q4 2019 reduction was Huntsman Corp, cutting an estimated $2.63M.
- Swift Run Capital Management fully exited Goldman Sachs in Q4 2019, selling an estimated $6.75M.
- Swift Run Capital Management's ten largest holdings make up 77% of its $76.3M portfolio in Q4 2019.
- Swift Run Capital Management opened 1 new position and closed 6 in Q4 2019.
- Swift Run Capital Management's portfolio value fell 29% quarter-over-quarter to $76.3M.
Based on Swift Run Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.